# A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl

Source: https://onco.cc/trials/nct05283720/  
OnCo record `nct05283720` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Epcoritamab, Lenalidomide, Ibrutinib in hodgkin lymphoma and non-hodgkin lymphoma, run by Genmab, active and no longer recruiting.

## Summary

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma is a phase 2 interventional study registered as NCT05283720 by Genmab, with 264 participants enrolled, started 2022-06-14 and due to reach its primary completion in 2032-11. Interventions recorded: Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05283720
- Phase: 2
- Setting: Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
- Sponsor: Genmab
- Enrolled: 264

## Sources

- ClinicalTrials.gov NCT05283720: https://clinicaltrials.gov/study/NCT05283720

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Prednisone](https://onco.cc/drugs/prednisone/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct05283720.json